Evidence map›Paper›PMID 38466882›Full record

ArticleHepatology communications2024

Crosstalk of lysyl oxidase-like 1 and lysyl oxidase prolongs their half-lives and regulates liver fibrosis through Notch signal.

Ning Zhang, Aiting Yang, Wen Zhang, Hong Li, Anjian Xu, Xuzhen Yan, Qi Han, Bingqiong Wang, Hong You, Wei Chen

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. [Exploring the advantages of traditional Chinese medicine and dual-anti therapy for liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ning ZhangLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Aiting YangState Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wen ZhangLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Hong LiState Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Anjian XuState Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Xuzhen YanState Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Qi HanLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Bingqiong WangLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Hong YouLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Wei ChenState Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLysyl oxidase (LOX) family members (LOX and LOXL1 to 4) are crucial copper-dependent enzymes responsible for cross-linking collagen and elastin. Previous studies have revealed that LOX and LOXL1 are the most dramatically dysregulated LOX isoforms during liver fibrosis. However, the crosstalk between them and the underlying mechanisms involved in the profibrotic behaviors of HSCs, as well as the progression of liver fibrosis, remain unclear.

methodspCol9GFP-HS4,5Tg mice, Loxl1fl/flGfapCre mice, human HSC line, and primary HSCs were enrolled to study the dysregulation pattern, profibrotic roles, and the potential mechanisms of LOX and LOXL1 interaction involved in the myofibroblast-like transition of HSCs and liver fibrogenesis.

resultsLOX and LOXL1 were synergistically upregulated during liver fibrogenesis, irrespective of etiology, together orchestrating the profibrotic behaviors of HSCs. LOX and LOXL1 coregulated in HSCs, whereas LOXL1 dominated in the coregulation loop. Interestingly, the interaction between LOXL1 and LOX prolonged their half-lives, specifically enhancing the Notch signal-mediated myofibroblast-like transition of HSCs. Selective disruption of Loxl1 in Gfap+ HSCs deactivated the Notch signal, inhibited HSC activation, and relieved carbon tetrachloride-induced liver fibrosis.

conclusionsOur current study confirmed the synergistic roles and the underlying mechanisms of LOXL1 and LOX crosstalk in the profibrotic behaviors of HSCs and liver fibrosis progression, providing experimental evidence for further clear mechanism-based anti-LOXL1 strategy development in the therapy of liver fibrosis.

Indexed as

Amino Acid OxidoreductasesProtein-Lysine 6-OxidaseAnimalsCarbon TetrachlorideCollagenExtracellular Matrix ProteinsHumansLiver CirrhosisMiceAmino Acid OxidoreductasesCarbon TetrachlorideCollagenExtracellular Matrix ProteinsLOXL1 protein, humanLoxl1 protein, mouseLOX protein, humanLox protein, mouseProtein-Lysine 6-Oxidase

Identifiers

PMID38466882
PMCPMC10932518
OpenAlexW4392638202

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.